Identifying mechanisms responsible for the clinical heterogeneity of chronic lymphocytic leukemia (CLL) is important to develop better treatments for this disease. Variations in responsiveness to immunoreceptor signaling may be responsible for differences in proliferation of CLL cells in vivo.
1 Accordingly, we examined the status of the B-cell calcium sensor (Ca o S) in primary CLL cells, as it responds to extracellular calcium (Ca o 2 þ ) fluctuations by modulating subsequent signal transduction through immunoreceptors. 2 In contrast to normal B cells, nearly half (23/51) of the CLL samples examined (with approval from the Sunnybrook Health Sciences Center Research Ethics Board) did not release intracellular calcium (Ca i 2 þ ) in response to CaCl 2 (labeled Ca o 2 þ non-responders) ( Table 1 ; Figure 1a ). This impaired Ca o S activity was not due to decreased stores of Ca i 2 þ in the endoplasmic reticulum, as the Ca 2 þ ATPase inhibitor, thapsigargin, was able to mobilize Ca i 2 þ in these cells (not shown). While normal B-cells mobilized Ca i 2 þ in response to as little as 250 mM CaCl 2 , Ca o 2 þ non-responder CLL cells remained insensitive to doses as high as 1.5 mM (above which, calcium was toxic) (not shown). These results suggested that the defective responses to Ca o 2 þ were not due to reduced expression or (Table 1) . Strikingly, intact Ca o 2 þ -sensing was associated with increased Rai stage, serum b 2 -microglobulin levels, CD38 expression and need for treatment, along with significantly shorter lymphocyte doubling times (LDTs) ( Table 1) , all of which are markers of more aggressive disease. 3 Increases in Ca o 2 þ responsiveness over time were observed in the CLL cells of six patients, associated with changes in clinical course such as shorter lymphocyte doubling times (LDTs) and need to institute chemotherapy (not shown).
We considered that a functional Ca o S might confer an aggressive phenotype by allowing CLL cells to respond more strongly to microenvironmental signals, such as antigens, cytokines and Toll-like receptor agonists. 1 Consistent with this hypothesis, changes in CD83 surface expression 4 h after stimulation by phorbol esters 2 (which mimic aspects of antigenic signaling
were much stronger than responses by Ca o 2 þ non-responsive CLL cells (Figure 1c) .
To further address this hypothesis, following a brief period of culture in Ca 2 þ (to trigger the Ca o 2 þ sensor) or in Ca 2 þ -free media (to prevent Ca o 2 þ sensor activation), CLL cells were activated with interleukin-2 and the Toll-like receptor-7 agonist, S28690, in Ca 2 þ -containing AIM-V media (to allow proper functioning of downstream signaling pathways that depend on calcium release-activated calcium channels interleukin-2 and S28690) 2 (Figures 1d and e) or survival under harsh culture conditions (Figure 1f) .
To help explain impaired Ca o 2 þ responsiveness of CLL cells, the stress-activated protein kinase, JNK, 5 was studied, as agents that activate this pathway (such as the protein kinase-C agonists, PMA and Bryostatin, ultraviolet light or heat shock) inhibited Ca o 2 þ sensing in normal B cells (Figures 2a and b) . In contrast to normal B cells, JNK was often phosphorylated (consistent with activation) in CLL samples, and expression of phosphorylated 46 and 54 kDa JNK isoforms correlated inversely with Ca o 2 þ responsiveness (Figures 2c and d) . The specific JNK inhibitor, SP600125, 5 restored Ca o 2 þ -induced Ca i 2 þ release (Figure 2e ) as well as transcription and translation of CD83 (Figures 2f and g ), a downstream target of the B-cell Ca o S. 2 These results support a possible inhibitory effect of activated JNK on the Ca o S in indolent CLL cells and an association of intact Ca o 2 þ sensing with the absence of JNK-mediated inhibition in aggressive cells, perhaps reflecting exposure of CLL cells in vivo to immunoreceptor ligands that can activate JNK, 1 as well as impaired JNK functioning that is known to accompany cancer progression. 6 These results are consistent with recent findings that high-risk CLL cells respond more strongly to activation of immunoreceptors, including the B-cell receptor 7 and Toll-like receptors. 8 In the absence of molecular identification of the Ca o S and direct measurement of Ca o 2 þ perturbations in CLL microenvironments in vivo, it is unclear whether Ca o 2 þ responsiveness in vitro has physiological relevance or is simply a manifestation of the enhanced signaling properties of more aggressive CLL cells. Although larger, prospective studies are required to confirm the observations, particularly regarding the possible role of JNK, our results suggest that the ability of CLL cells to respond to Ca o 2 þ perturbations may be informative with respect to clinical outcome. For example, a 'switch' to Ca o 2 þ responsiveness may herald disease progression and a need to institute chemotherapy. Potentially, Ca o S inhibitors might allow aggressive forms of CLL, with poor prognosis, to be converted to more indolent types with a better outcome.
